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With  the  possible  introduction  of  exon  skipping  therapy  in 
Duchenne muscular dystrophy, it has become increasingly im-
portant to know the role of each exon of the dystrophin gene 
to protein expression, and thus the phenotype. In this report, 
we present two related men with an unusually mild BMD as-
sociated with an exon 26 deletion. The proband, a 23-year-old 
man, had slightly delayed motor milestones, walking 1½ years 
old. He had no complaints of muscle weakness, but had muscle 
pain. Clinical examination revealed no muscle wasting or loss 
of power, but his CK was 1500-7000 U/l. Muscle biopsy showed 
dystrophic changes. He had comorbidity with dystonia, slight 
mental retardation, low stature and neuropathy.  The  brother 
of the proband’s mother came to medical attention when he was 
43 years old. He complained about muscle pain. On examina-
tion, a MRC grade 4+ hip extention palsy and a discrete calf 
hypertrophy was noted. Creatine kinase was normal or raised 
maximally to 500U/l. The muscle biopsy was myopathic with 
increased fiber size variation and many internal nuclei, but no 
dystrophy. No comorbidity was found. In both cases, western 
blot  showed  a  reduced  dystrophin  band.  Genetic  evaluation 
revealed a deletion of exon 26 of the dystrophin gene in both. 
This is the first description of patients with a exon 26 deletion 
of the dystrophin gene. Assuming the proband’s comorbidity is 
unrelated, exon 26 deletion results in a very mild phenotype. 
This might be of interest in planning exon skipping therapy 
for Duchenne muscular dystrophy. This report also shows that 
BMD may present with a normal CK. 
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Introduction
No curative treatment is available for the two dystrophi-
nopathies, Becker and Duchenne muscular dystrophies. In 
1995, low-dose steroid treatment was shown to diminish 
deterioration  of  muscle  strength  in  Duchenne  muscular 
dystrophy (1), and is now routinely offered to many, pref-
erentially  ambulatory,  patients.  Symptomatic  treatment 
such as ventilatory support and physiotherapy has also led 
to improvements of life quality and survival. In spite of this 
progress, however, the dystrophinopathies progress relent-
lessly and typically result in severe disability. A promising 
new treatment is exon-skipping therapy which is based on 
converting an “out-of-frame” mutation into an “in-frame” 
mutation, and thus transforming a severe Duchenne phe-
notype to a mild Becker phenotype. Phase 1-2 trials are 
ongoing to investigate the feasibility of exon skipping for 
Duchenne (2, 3). With the possible introduction of exon 
skipping therapy, it has become increasingly important to 
know the exact role of each exon of the dystrophin gene on 
protein expression, and thus the phenotype. 
In this report, we present two related men with an 
unusually mild Becker muscular dystrophy phenotype as-
sociated with a novel exon 26 deletion.
Methods 
After informed consent, we studied the phenotype 
of the index person and his maternal uncle. The disease 
history was obtained in a formal interview and clinical 
examination was carried out with estimation of muscle 
strength and evaluation of muscle bulk. Needle biopsies 
were performed in the lateral vastus muscle. Multiplex 
western  blots  were  performed  as  described  by Ander-
son  (4).  An  electrocardiogram  and  echocardiography 
were performed in both patients.
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results
The proband, a 23-year-old man, had slightly de-
layed motor milestones, walking 1½ years old. He had 
no  complaints  of  muscle  weakness,  but  had  muscle 
pain. Clinical examination, at the age of 16 years, re-
vealed no muscle wasting or loss of power, but his crea-
tine kinase was increased to 1500-7000 U/l (< 400). His 
muscle biopsy showed dystrophic changes (Fig. 1A). 
He had co-morbidity with segmental dystonia includ-
ing torticollis, slight mental retardation, low stature and 
axonal neuropathy verified by ENG. His dystonia was 
treated with Clonazepam, Orphenadrin and botulinum 
injections. At  age  20,  he  still  had  preserved  muscle 
strength and bulk. 
The brother of the proband’s mother came to medical 
attention when he was 43 years old. He complained about 
muscle pain. On examination, a MRC grade 4+ hip ex-
tension palsy and a discrete calf hypertrophy (Fig. 2) was 
noted. Creatine kinase was normal or increased to maxi-
mally 500 U/l. The muscle biopsy was myopathic with 
increased fiber size variation and multiple internal nuclei, 
but no dystrophic changes as seen in his nephew (Fig. 1B). 
No co-morbidity was found. In both cases, western blot 
revealed a marginally reduced size of dystrophin, with a 
severely decreased expression level to less than 5% of nor-
mal. α-Sarcoglycan, β-dystroglycan, Calpain and merosin 
were down-regulated in parallel (Fig. 3). Genetic evalua-
tion, through MPLA and direct PCR, revealed a deletion 
of exon 26, (c.3433-?_3603+?del) of the dystrophin gene 
in both patients. The mutation is predicted to induce an 
in-frame transcript. 
Discussion 
Mutations  involving  exon  26  have  been  described 
several times (5), most often leading to a Duchenne phe-
notype. These  mutations  introduce  premature  stop  co-
dons (6-8) or disrupts correct reading, all leading to loss 
of functional dystrophin protein. Here we present the first 
report of patients hemizygous for a deletion in exon 26. 
Figure 2. The maternal uncle of the proband showing 
slight hypertrophy of his calves.
Figure 3. Western blots of the proband (3A) and his ma-
ternal uncle (3B). The blots show weak dystrophin bands 
with  a  slightly  shorter  dystrophin  than  the  wild-type. 
α-Sarcoglycan  and  β-dystroglycan  are  down-regulated 
secondary to the dystrophin loss.CTRL, control.
Figure  1.  HE  stained  muscle  section  from  the  vas-
tus lateralis muscle. 1A is from the proband, showing 
marked fibre size variability, central nuclei and fibrosis. 
1B is from his maternal uncle, showing milder changes 
without fibrosis.Nanna Witting et al.
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The deletion is predicted to result in an “in-frame” tran-
script of the dystrophin gene. Exon 26 is part of the cen-
tral rod domain of dystrophin that connects the actin at the 
sarcomer to the glycoprotein complex at the membrane. 
The exact function of exon 26 or the central rod domain 
is not entirely understood, and the consequence of exon 
26 deletion can therefore not be predicted theoretically. 
Assuming the proband’s co-morbidity is unrelated to the 
dystrophinopathy, our findings suggest that exon 26 dele-
tion results in a very mild phenotype. 
According to human genome mutation database (HG-
MD) 23 different point mutations or smaller insertion/
deletion mutations are located in exon 26 all but a few re-
sulting in a Duchenne phenotype. Our finding implicates 
that patients with these mutations could potentially ben-
efit from an exon-skipping therapy in which exon 26 is 
skipped, with the aim of ameliorating the phenotype from 
Duchenne to a Becker muscular dystrophy. Our finding 
has therefore potentially positive therapeutic implications 
for a selection of Duchenne patients. 
Another interesting finding is the normal CK in one 
of our subjects. We have previously reported normal CK 
levels with deletion of exon 16 of the dystrophin gene (9). 
The index person was an asymptomatic 26 year old woman 
who volunteered to donate reference material for genetic 
analysis. Thus the finding of the exon 16 deletion was acci-
dental. Her 60-year-old father also was hemizygous for the 
same deletion and like his daughter had normal CK, muscle 
biopsy and clinical examination. Normal CK and clinical 
evaluation have also been described with deletion of exons 
49-51 in a grandfather, whereas the younger members of 
the family were symptomatic with elevated CK (10). Nor-
mal CK level in asymptomatic individuals with aberrations 
of the dystrophin gene is therefore known. In contrast, nor-
mal CK in symptomatic Becker patients have not been re-
ported before. This finding has important implications for 
clinical practice, because a raised CK normally is consid-
ered obligatory for Becker muscular dystrophy. 
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